¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"thyroid carcinoma risk factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • risk ratio
    À§Çèºñ
  • apocrine carcinoma
    ¾ÆÆ÷Å©¸°¾ÏÁ¾
  • acinar cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • adenocystic carcinoma
    »ù³¶¾ÏÁ¾, ¼±³¶¾ÏÁ¾
  • adenoid cystic carcinoma
    »ù³¶¾ÏÁ¾, ¼±³¶¾ÏÁ¾
  • adenoma-carcinoma sequence
    »ùÁ¾¾ÏÁ¾¿¬¼â, ¼±Á¾¾ÏÁ¾¿¬¼â
  • adnexal carcinoma
    ºÎ¼Ó±â°ü¾ÏÁ¾
  • anaplastic carcinoma
    ¿ªÇü¼º¾ÏÁ¾
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • bronchioloalveolar carcinoma
    ¼¼±â°üÁöÆóÆ÷¾ÏÁ¾, ¼¼±â°üÁö²Ê¸®¾ÏÁ¾
  • bronchoalveolar carcinoma
    ±â°üÁöÆóÆ÷¾ÏÁ¾
  • bronchogenic carcinoma
    ±â°üÁöÀ¯·¡¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷»óÇdz»¾ÏÁ¾, ÆíÆò¼¼Æ÷¾ÏÁ¾
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • tubular carcinoma
    °ü¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • benefit/risk ratio
    À¯ÀÍÀ¯ÇغñÀ²
  • radiation risk coefficient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • explosion risk
    Æø¹ßÀ§Çèµµ
  • relative risk estimation
    »ó´ëÀ§ÇèµµÃßÁ¤
  • risk factor
    À§ÇèÀÎÀÚ
  • high risk group
    °íÀ§Çèµµ±º
  • lifetime risk
    Æò»ýÀ§Çèµµ
  • multiple risk
    ´ÙÁßÀ§Çèµµ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§Ç赵ǥÁö
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • operative risk
    ¼ö¼úÀ§Çèµµ
  • physical hazard risk
    ¹°¸®ÀûÀ¯ÇØÀ§Çèµµ
  • population attributable risk
    ÀϹÝÀα¸±â¿©À§Çèµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • human thyroid stimulating hormone =HTSH
    °©»ó¼±ÀÚ±ØÈ£¸£¸ó.
  • human thyroid stimulating hormone =HTSH
    »ç¶÷°©»ó¼±ÀÚ±ØÈ£¸£¸ó.
  • pretracheal thyroid gland
    ±â°ü¾Õ°©»ó»ù
  • Meibomian gland carcinoma
    ¸¶À̺½¼± ¾Ï(Á¾)
  • Merkel cell carcinoma
    ¸Þ¸£Ä̼¼Æ÷ ¾Ï(Á¾)
  • acinar carcinoma
    ¼±¹æ¾ÏÁ¾(¼±¹æ¾ÏÁ¾).
  • acinic cell carcinoma
    ¼±¹æ¼¼Æ÷¾ÏÁ¾(¡­á¬øàäßðþ)
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç(ÛöÕË ðþåÆ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenocystic carcinoma
    ¼±³¶Á¾¼º¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid cystic carcinoma
    ¼±¾ç³¶¼º¾ÏÁ¾(àÍåÆÒ¥àõäßðþ)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • adenoma-carcinoma sequence
    ¼±Á¾-¾ÏÁ¾ ¿¬¼â(àÍðþ-äßðþ ææáð)
  • adnexal carcinoma
    ºÎ¼Ó±â(ݾáÕÐï) ¾Ï
  • apocrine gland carcinoma
    ¾ÆÆ÷Å©¸°¼±(~ àÍ) ¾Ï(Á¾)(äß(ðþ))
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative risk
    ºñ±³À§Çèµµ(ËÓË´Ëô̴̬).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • risk factor
    À§ÇèÀÎÀÚ
  • risk management
    À§Çè°ü¸®.
  • risk-benefit analysis
    À§Çè-À̵æºÐ¼®
  • surgical risk
    ¼ö¼úÀ§Çèµµ(¼ö¼úÀ§ÇèŹ).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • aberrant thyroid
    À̼Ҽº°©»ó¼±
  • absence of thyroid gland
    °©»ó»ù°á¿©Áõ
  • accessory thyroid
    ºÎ¼ö°©»ó¼±(ºÎ¼ö°©»ó¼±).
  • accessory thyroid gland
    µ¡°©»ó»ù, ºÎ°©»ó¼±(ÜùË£ßÒàÍ).
  • accessory thyroid gland
    µ¡°©»ó»ù
  • artery, cricothyroid branch of superior thyroid
    »ó°©»ó¼±µ¿¸ÆÀÇ À±»ó°©»óÁö, À§
  • azygous thyroid plexus
    Ȧ°©»óÁ¤¸Æ¾ó±â
  • cold thyroid nodule
    ºñ±â´É¼º °©»ó¼±°áÀý.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
FMTC Familial Medullary Thyroid Carcinoma
MTC Medullary Thyroid Carcinoma
DTC day treatment center; differential thyroid carcinoma
FTC Federal Trade Commission; follicular thyroid carcinoma; frequency threshold curve; frequency tuning ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DMF Dose modification factors
EF Enhancement factors
EGFR Epidermal growth factors receptor
GF Growth Factors
GDF Growth and differentiation factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acinar carcinoma
    ¼±¹æ ¾ÏÁ¾
    ÃéÀå ¾ÏÁ¾ Áß µå¹°°Ô ¾ÏÁ¾ÀÌ ¼±¹æ¼¼Æ÷¿¡¼­ ¹ß»ýÇÏ´Â °Í. À̵é Á¾¾çÀº Á¾¾ç ¼¼Æ÷µéÀÌ ¶×¶×ÇÏ°í ´Ù°¢ÇüÀ̸ç È£»ê¼º ¼Ò°ßÀ» º¸ÀÌ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù.
  • acinic cell carcinoma
    ¼±¹æ ¼¼Æ÷ ¾ÏÁ¾
    1. ¼±¹æ ¼¼Æ÷, ±Ù»óÇǼ¼Æ÷°¡ Áõ½ÄÇÏ¿© Çü¼ºµÇ°í ³·Àº ¾Ç¼ºµµ¸¦ º¸ÀδÙ. 2. Ÿ¾×¼± ¾à¼º Á¾¾ç Áß 5¹øÂ°ÀÇ ¹ß»ý ºñÀ²À» °®´Â Á¾¾çÀ¸·Î 90%¿¡¼­ ÀÌÇϼ±¿¡¼­ ¹ß»ýÇÏ¸ç ¾ÇÇϼ±°ú ¼ÒŸ¾×¼±¿¡¼­µµ µå¹°°Ô ¹ß»ýÇÑ´Ù. ¿©¼º¿¡¼­ ´Ù¼Ò È£¹ßÇϰí, ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇϳª ÁÖ·Î 30-70´ë¿¡ °ñ°í·ç ¹ß»ýÇÑ´Ù. ¿¹Àü¿¡´Â ¾ç¼ºÀ¸·Î »ý°¢ÇÏ¿© ¼±¹æ¼¼Æ÷Á¾À̶ó ºÎ¸¥ ÀûÀÌ ÀÖÀ¸³ª ºÐ¸íÇÑ ¾Ç¼ºÀ¸·Î ¼±¾ÏÁ¾À¸·Î ºÎ¸¥´Ù. Á¾¾ç ¼¼Æ÷´Â Àå¾×¼º ¼±¹æ¼¼Æ÷¿Í À¯»çÇÏÁö¸¸ ¿©·¯ °¡Áö ´Ù¸¥ ¼¼Æ÷µéÀÌ ³ªÅ¸³ª¸ç, °³Á¦°ü ¿¹ºñ¼¼Æ÷¿¡¼­ ±â¿øÇÑ´Ù°í º»´Ù.
  • acinous carcinoma
    ¼±¹æ»ó ¾ÏÁ¾
    ¼¼Æ÷°¡ ¼±¹æ ±¸Á¶¸¦ Çü¼ºÇϵ簡 ȤÀº ¼¼Æ÷°¡ È®½ÇÈ÷ ¼±¹æ¼¼Æ÷¿¡¼­ »ý°Ü³µ´Ù°í »ý°¢µÇ´Â ¾Ç¼º Á¾¾ç.
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç ±âÀú¼¼Æ÷¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenoma-carcinoma sequence
    ¼±Á¾-¾ÏÁ¾ ¿¬¼â
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • adnexal carcinoma
    ºÎ¼Ó±â ¾Ï
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • anaplastic carcinoma
    ¿ªÇü¼º ¾ÏÁ¾
    µå¹°°Ô ¹ß»ý. È£¹ß ¿¬·ÉÀº 60-70´ëÀ̰í ÀÎüÀÇ ¾ÏÁß ¾Ç¼ºµµ°¡ ¾ÆÁÖ ³ôÀº ÂÊ¿¡ ¼ÓÇÏ¸ç ¹ÌºÐÈ­ ¾ÏÁ¾À̶ó°í ÇÑ´Ù. ÀÓ»óÀûÀ¸·Î ÀÎÁöµÉ ¶§ °©»ó¼± »Ó ¾Æ´Ï¶ó ÁÖº¯ Á¶Á÷±îÁö ħÅõÇÏ¿© Å« µ¢¾î¸®¸¦ Çü¼ºÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¼Ò ¼¼Æ÷ ¾ÏÁ¾
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • basal cell carcinoma
    ±âÀú ¼¼Æ÷ ¾Ï, ±âÀú ¼¼Æ÷ ¾ÏÁ¾
    1. »óÇÇÀÇ ±âÀú ¼¼Æ÷¸¦ ´àÀº ±âº» ±¸Á¶¸¦ °¡Áö´Â »óÇÇ ¼¼Æ÷ ½Å»ý¹°. À̰ÍÀº »óÇÇ ¼¼Æ÷ÀÇ ±âÀú ¼¼Æ÷, ¸ð³¶À̳ª ÇÇÁö¼±ÀÇ ¿Ü¹æ ¼¼Æ÷, ƯÈ÷ ¾È¸éÀÇ °¡¿îµ¥ 1/3¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô ÀüÀ̵ÇÁö¸¸ ±¹¼ÒÀûÀ¸·Î ħ¹üÇÑ´Ù. ±¸°­ Á¡¸·¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê´Â´Ù. Çѱ¹ÀÎ ÇǺΠ¾Ç¼º Á¾¾ç Áß °¡Àå ¸¹Àº ÇüÀÌ´Ù. ÀüÀ̰¡ Àß ¾ÈµÇ¸ç Àç¹ßÀ²ÀÌ ÀûÀº Áß°£ ¾Ç¼ºµµÀÌ´Ù. ±¸°­ÀÇ ±âÀú ¼¼Æ÷ ¸ð¹Ý ÁõÈıº°ú °ü·ÃÀÌ ÀÖ´Ù. 2. Ç¥ÇÇ ±âÀúÃþÀÇ ¾Ç¼º Á¾¾ç.
  • basaloid squamous carcinoma
    ±âÀú »óÇÇ ¼¼Æ÷ ¾ÏÁ¾
    Çô, ÀεÎ, Èĵο¡ ¹ß»ýÇÏ¸ç ³ôÀº ¾Ç¼ºµµ¸¦ º¸ÀδÙ.
  • basosquamous carcinoma
    ±âÀú ÆíÆò ¼¼Æ÷ ¾ÏÁ¾
    Á¶Á÷ÇÐÀûÀ¸·Î ±âÀú ¼¼Æ÷¿Í ÆíÆò ¼¼Æ÷ÀÇ ¿ä¼Ò¸¦ ¸ðµÎ °¡Áö°í ÀÖ´Â ¾ÏÁ¾. ±¸°­³»¿¡¼­ Á¾Á¾ °üÂûµÇ¸ç ±âÀú ¼¼Æ÷ ¾ÏÁ¾º¸´Ù ÀüÀ̰¡ ´õ Àß µÇ´Â °ÍÀ¸·Î »ý°¢µÇ°í ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
biotic factors Environmental factor's or influences resulting from the activities of living organisms, as contrasted to those resulting from climatic, geological, or other factor's.
(05 Mar 2000)
blood coagulation factors Endogenous substances, usually proteins, that participate in the blood coagulation process.
(12 Dec 1998)
macrophage migration-inhibitory factors Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell.
(12 Dec 1998)
recognition factors Factors which effect "recognition" of target antigens by polymorphonuclear leukocytes; apparently the Fc portion of antibody molecules and the activated third component of complement (C3), for both of which phagocytes have receptor sites.
(05 Mar 2000)
releasing factors Hormones produced by the hypothalamus whichstimulate the release of other hormones in the pituitary gland.
(09 Oct 1997)
resistance factors Plasmid's carrying genes responsible for antibiotic (or antibacterial drug) resistance among bacteria (notably Enterobacteriaceae); they may be conjugative or nonconjugative plasmid's, the former possessing transfer genes (resistance transfer factor) lacking in the latter.
Synonym: R factors, R plasmids, resistance factors, resistance-transferring episomes.
(05 Mar 2000)
peptide elongation factors Protein factors uniquely required during the elongation phase of protein synthesis.
(12 Dec 1998)
peptide initiation factors Protein factors uniquely required during the initiation phase of protein synthesis.
(12 Dec 1998)
peptide termination factors Proteins that are exclusively involved in the termination reactions of protein synthesis on the ribosome.
(12 Dec 1998)
C factors Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc.
Synonym: C factors.
(05 Mar 2000)
r factors A class of plasmids that transfer antibiotic resistance from one bacterium to another by conjugation.
(12 Dec 1998)
rheumatoid factors Antibodies in the serum of individuals with rheumatoid arthritis that react with antigenic determinants or immunoglobulins that enhance agglutination of suspended particles coated with pooled human gamma-globulin. Rheumatoid factors also occur in other autoimmune and certain infectious diseases.
(05 Mar 2000)
chemotactic factors Chemical substances that attract or repel cells or organisms. The concept denotes especially those factors released as a result of tissue injury, invasion, or immunologic activity, that attract leukocytes, macrophages, or other cells to the site of infection or insult.
(12 Dec 1998)
chemotactic factors, eosinophil Cytotaxins liberated from normal or invading cells that specifically attract eosinophils; they may be complement fragments, lymphokines, neutrophil products, histamine or other; the best known is the tetrapeptide ecf-a, released mainly by mast cells.
(12 Dec 1998)
chemotactic factors, macrophage Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á